Comparison Overview
Astellas Pharma
Astellas Pharma
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo, JP, 103-8411
Last Update: 05/04/2026
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and develo...
Novartis
Novartis Campus, Basel, 4002, CH
Last Update: 20/05/2026
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million pe...
Compliance Ranges Comparison
Astellas Pharma
Novartis
Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Astellas Pharma in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
Novartis has 3.85% fewer incidents than the average of all companies with at least one recorded incident.
Incident History - Astellas Pharma (X = Date, Y = Severity)
Astellas Pharma cyber incidents detection timeline including parent company and subsidiaries.
Incident History - Novartis (X = Date, Y = Severity)
Novartis cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents
Astellas Pharma
Novartis
FAQ
Latest Global CVEs
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an inadequate encryption strength vulnerability which could allow an attacker to steal admin credentials via weak hash or a pass-the-hash attack.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could allow for asset discovery by unauthenticated users.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.
Pronetiqs IntraVUE Versions 3.2.1a14 and prior have a plaintext storage of a password vulnerability that could expose cleartext credentials through the API.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could expose the underlying host/share filesystem.